Jensen PB - Search Results

1

Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.

Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M. Hofland K, et al. Among authors: jensen pb. Clin Cancer Res. 2000 Apr;6(4):1488-97. Clin Cancer Res. 2000. PMID: 10778981

2

Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.

Hofland KF, Thougaard AV, Sehested M, Jensen PB. Hofland KF, et al. Among authors: jensen pb. Clin Cancer Res. 2005 May 15;11(10):3915-24. doi: 10.1158/1078-0432.CCR-04-2343. Clin Cancer Res. 2005. PMID: 15897593

3

Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.

Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PE, Rengtved P, Sehested M, Jensen PB. Hofland KF, et al. Among authors: jensen pb, jensen lh. Clin Cancer Res. 2005 Sep 15;11(18):6722-9. doi: 10.1158/1078-0432.CCR-05-0698. Clin Cancer Res. 2005. PMID: 16166453

4

Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.

Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH. Jensen PB, et al. Among authors: jensen ps. Cancer Res. 1990 Jun 1;50(11):3311-6. Cancer Res. 1990. PMID: 2159380

5

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Sorensen M, Sehested M, Jensen PB. Sorensen M, et al. Among authors: jensen pb. Br J Cancer. 1995 Aug;72(2):399-404. doi: 10.1038/bjc.1995.345. Br J Cancer. 1995. PMID: 7640225 Free PMC article.

6

In vitro models for testing of cytostatic agents in small cell lung cancer.

Jensen PB, Sehested M. Jensen PB, et al. Cancer Treat Res. 1995;72:171-91. doi: 10.1007/978-1-4615-2630-8_9. Cancer Treat Res. 1995. PMID: 7702986 Review. No abstract available.

7

Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindeløv L. Jensen PB, et al. Br J Cancer. 1993 Feb;67(2):311-20. doi: 10.1038/bjc.1993.58. Br J Cancer. 1993. PMID: 8094293 Free PMC article.

8

Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.

Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJ, Hansen HH. Jensen PB, et al. Cancer Res. 1994 Jun 1;54(11):2959-63. Cancer Res. 1994. PMID: 8187081

9

DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.

Jensen PB, Sehested M. Jensen PB, et al. Biochem Pharmacol. 1997 Oct 1;54(7):755-9. doi: 10.1016/s0006-2952(97)00116-0. Biochem Pharmacol. 1997. PMID: 9353129 Review.

10

Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.

Wessel I, Jensen PB, Falck J, Mirski SE, Cole SP, Sehested M. Wessel I, et al. Among authors: jensen pb. Cancer Res. 1997 Oct 15;57(20):4451-4. Cancer Res. 1997. PMID: 9377550

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters